- Trial phase
- Approved
- Time to market
- Already approved and marketed (injectable since 2021; oral pill since January 2026).
- Why 4/10
- Wegov is fully approved and marketed in multiple formulations (injectable 2.4mg,7.2mg; and oral26mg tablets launched Jan206), there is na FDA PDUFA or pivotal fell readout pending for this drug. The ext hard catalyst is Q3 206 earnings (~Nov4,206), a commercial update wich impacts stock but is nt abinary regulatory event, topping impact at 4.
The next major catalyst for NVO shares tied to Wegovy is the Q3 2026 earnings report expected around November 4, 2026, where investors will scrutinize oral Wegovy pill sales trajectory and whether injectable Wegovy market share is stabilizing against Zepbound competition. Longer-term, watch for China approval of oral Wegovy and the Viatris patent challenge.
Price Chart
Executive Summary
Wegovy (semaglutide) is Novo Nordisk's blockbuster GLP-1 receptor agonist franchise for chronic weight management, approved in multiple forms: injectable 2.4 mg (FDA 2021), higher-dose injectable 7.2 mg (FDA March 2026), and the oral pill 25 mg (FDA December 2025, launched January 2026), the first-ever oral GLP-1 for obesity. The drug also carries a cardiovascular risk-reduction label from the landmark SELECT trial. Despite commercial success, NVO stock is down ~38% over three years and trades near the low end of its 52-week range ($35.12–$64.16) as investors contend with fierce competition from Eli Lilly's Zepbound (tirzepatide), upcoming patent challenges from Viatris, and oral Wegovy pill sales that missed early expectations. The analyst consensus is 'hold' with a mean price target of ~$44.93 (14.8% upside from the current ~$38.67).
How It Works
Wegovys active ingredient, semaglutide, mimics a natural hormone called GLP-1 that the body releases after eating. It slws stomach emptying, increases feelings of fullness, and reduces appetite by signaling to the brain that you're full. The result is lower calorie intake and weight loss. It also reduces inflammation and cardiovascular risk through additional mechanisms that are not fully understood.
Trial Status
Wegovy is fully approved and commercially available in the U.S. across injectable (2.4 mg, 7.2 mg) and oral (25 mg tablet) formulations. Post-marketing studies continue, including STEP Young trial in children aged 6-12 (positive results announced Sept 2026) and real-world evidence comparisons vs tirzepatide. The drug also has an approved cardiovascular risk-reduction indication based on the SELECT outcomes trial.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report (~November 4, 2026), oral Wegovy pill sales trajectory and overall GLP-1 franchise revenue
- China NMPA decision on oral Wegovy marketing application (filed August 2026)
- Viatris patent litigation over generic Wegovy (filed September 2026)
- Continued competitive dynamics as Eli Lilly's oral Foundayo receives EU CHMP recommendation (Oct 2026) and potential US FDA decision
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S COURT-RULING NVO ·Originating report